Kymriah Gets Accelerated Approval for Relapsed/Refractory Follicular Lymphoma
The Food and Drug Administration (FDA) has granted accelerated approval to Kymriah® (tisagenlecleucel), a CD19-directed genetically modified autologous T-cell immunotherapy, for the treatment of adults with relapsed or refractory follicular lymphoma after 2 or more…